Rakovina Therapeutics Inc. | WebDisclosure

Basculer en Français

10443	Companies
219236	Keywords
148695	Articles
115969	Press releases

Headlines Articles Press releases Rakovina Therapeutics Inc.

Home
Companies
Rakovina Therapeutics Inc.

BRIEF

published on 04/02/2025 at 15:36, 1 year 1 month ago

Rakovina Therapeutics Receives Buy Rating from First Berlin Equity Research

Artificial Intelligence DNA Damage Response Rakovina Therapeutics PARP And ATR Biotech Investment
BRIEF

published on 04/02/2025 at 15:36, 1 year 1 month ago

Rakovina Therapeutics reçoit la recommandation d'achat de First Berlin Equity Research

Intelligence Artificielle Rakovina Therapeutics Réponse Aux Dommages À L'ADN PARP Et ATR Investissement En Biotechnologie
PRESS RELEASE

published on 04/02/2025 at 15:31, 1 year 1 month ago

Original-Research: Rakovina Therapeutics Inc. (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research initiates coverage on Rakovina Therapeutics Inc. with a Buy recommendation and CAD 0.40 target price. Rakovina focuses on DNA Damage Response pathways in developing next-gen cancer treatments

First Berlin Equity Research Buy Recommendation Rakovina Therapeutics Inc. DNA Damage Response Pathways CAD 0.40 Target Price

Accesswire

Published on 05/23/2026 at 03:15, 8 hours 6 minutes ago

UraniumX Approved for Trading on the OTCQB Venture Market and Announces Board Change
Published on 05/23/2026 at 03:00, 8 hours 21 minutes ago

Battery X Metals Reports Up to ~84 km Estimated Driving Range Increase Across Multiple BYD Electric Vehicles Following Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Trials, Demonstrating Performance Improvement Across the World’s Larges
Published on 05/23/2026 at 02:25, 8 hours 56 minutes ago

Battery X Metals Announces up to $2 Million Private Placement Financing and Initiative to Strengthen Balance Sheet
Published on 05/23/2026 at 02:25, 8 hours 56 minutes ago

Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec
Published on 05/23/2026 at 01:00, 10 hours 21 minutes ago

LIR Life Sciences Announces Initiation of Phase 1 Macromolecule-Enabled Transdermal Delivery Development with Neuland Laboratories

View all ACCESSWIRE

EQS Group

Published on 05/22/2026 at 22:05, 13 hours 16 minutes ago

Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH
Published on 05/22/2026 at 22:05, 13 hours 16 minutes ago

Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
Published on 05/22/2026 at 19:51, 15 hours 30 minutes ago

Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Redemption Prices
Published on 05/22/2026 at 18:33, 16 hours 48 minutes ago

Update on Coupon payment due on 23 May 2026 and Preparation of the Green Bond Restructuring
Published on 05/22/2026 at 18:30, 16 hours 51 minutes ago

Annual General Meeting of Curatis Holding AG approved all proposals of the Board of Directors

Les Echos

Published on 05/22/2026 at 19:35, 15 hours 46 minutes ago

PROJET D'EVOLUTION DE SA GOUVERNANCE ET LA NOMINATION D'UN PRESIDENT DU DIRECTOIRE PAR INTERIM
Published on 05/22/2026 at 18:05, 17 hours 16 minutes ago

Déclaration hebdomadaire d'opérations effectuées du 18 au 22 mai 2026
Published on 05/22/2026 at 18:05, 17 hours 16 minutes ago

Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 22 hours 29 minutes ago

Communiqué du Conseil d’administration – Assemblée Générale du 22 mai 2026
Published on 05/22/2026 at 12:52, 22 hours 29 minutes ago

Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026

View all LES ECHOS COMFI WIRE